Trials / Completed
CompletedNCT01267396
Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions
Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Dr. Reddy's Laboratories Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to compare and evaluate the single-dose oral bioavailability of the test formulation of Sertraline Hydrochloride 100 mg tablets (Dr. Reddy's Laboratories Limited) with the reference formulation ZOLOFT® 100 mg Tablet (Pfizer)under fasting conditions in healthy adult human subjects.
Detailed description
Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover, Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects. 32 healthy, adult, human male subjects were enrolled in the study and all the subjected completed all the periods.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sertraline | Sertraline Hydrochloride Tablets 100 mg |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2006-09-01
- Completion
- 2006-10-01
- First posted
- 2010-12-28
- Last updated
- 2012-01-11
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT01267396. Inclusion in this directory is not an endorsement.